SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Barr E. L. M.) "

Sökning: WFRF:(Barr E. L. M.)

  • Resultat 581-590 av 591
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
581.
  • Wheeler, Cosette M., et al. (författare)
  • The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years
  • 2009
  • Ingår i: Journal Of Infectious Diseases. - : Oxford University Press (OUP). - 0022-1899 .- 1537-6613. ; 199:7, s. 936-944
  • Konferensbidrag (refereegranskat)abstract
    • Background. We evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) associated with >20% of cervical cancers. The population evaluated included HPV-naive women and women with preexisting HPV infection and/or HPV-related disease at enrollment. Methods. Phase 3 efficacy studies enrolled 17,622 women aged 16-26 years. Subjects underwent cervicovaginal sampling and Pap testing on day 1 and then at 6-12-month intervals for up to 4 years. HPV typing was performed on samples from enrollment and follow-up visits, including samples obtained for diagnosis or treatment of HPV-related disease. All subjects who received >= 1 dose and returned for follow-up were included. Results. Vaccination reduced the rate of HPV-31/33/45/52/58 infection by 17.7% (95% confidence interval [CI], 5.1% to 28.7%) and of cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS) by 18.8% (95% CI, 7.4% to 28.9%). Vaccination also reduced the rate of HPV-31/58/59-related CIN1-3/AIS by 26.0% (95% CI, 6.7% to 41.4%), 28.1% (95% CI, 5.3% to 45.6%), and 37.6% (95% CI, 6.0% to 59.1%), respectively. Although a modest reduction in HPV-31/33/45/52/58-related CIN2 or worse was observed, the estimated reduction was not statistically significant. Conclusions. These cross-protection results complement the vaccine's prophylactic efficacy against disease associated with HPV-6, -11, -16, and - 18. Long-term monitoring of vaccinated populations are needed to fully ascertain the population-based impact and public health significance of these findings.
  •  
582.
  • Bernatsky, Sasha, et al. (författare)
  • Cancer risk in systemic lupus: An updated international multi-centre cohort study
  • 2013
  • Ingår i: Journal of Autoimmunity. - : Elsevier BV. - 0896-8411. ; 42, s. 130-135
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: To update estimates of cancer risk in SLE relative to the general population. Methods: A multisite international SLE cohort was linked with regional tumor registries. Standardized incidence ratios (SIRs) were calculated as the ratio of observed to expected cancers. Results: Across 30 centres, 16,409 patients were observed for 121,283 (average 7.4) person years. In total, 644 cancers occurred. Some cancers, notably hematologic malignancies, were substantially increased (SIR 3.02, 95% confidence interval, CI, 2.48, 3.63), particularly non-Hodgkin's lymphoma, NHL (SIR 4.39, 95% CI 3.46, 5.49) and leukemia. In addition, increased risks of cancer of the vulva (SIR 3.78, 95% CI 1.52, 7.78), lung (SIR 1.30, 95% CI 1.04, 1.60), thyroid (SIR 1.76, 95% CI 1.13, 2.61) and possibly liver (SIR 1.87, 95% CI 0.97, 3.27) were suggested. However, a decreased risk was estimated for breast (SIR 0.73, 95% CI 0.61-0.88), endometrial (SIR 0.44, 95% CI 0.23-0.77), and possibly ovarian cancers (0.64, 95% Cl 0.34-1.10). The variability of comparative rates across different cancers meant that only a small increased risk was estimated across all cancers (SIR 1.14, 95% CI 1.05, 1.23). Conclusion: These data estimate only a small increased risk in SLE (versus the general population) for cancer over-all. However, there is clearly an increased risk of NHL and cancers of the vulva, lung, thyroid, and possibly liver. It remains unclear to what extent the association with NHL is mediated by innate versus exogenous factors. Similarly, the etiology of the decreased breast, endometrial, and possibly ovarian cancer risk is uncertain, though investigations are ongoing. (C) 2013 Elsevier Ltd. All rights reserved.
  •  
583.
  •  
584.
  • Atun, Rifat, et al. (författare)
  • Sustainable care for children with cancer : a Lancet Oncology Commission
  • 2020
  • Ingår i: The Lancet Oncology. - 1470-2045. ; 21:4, s. 185-224
  • Forskningsöversikt (refereegranskat)abstract
    • We estimate that there will be 13·7 million new cases of childhood cancer globally between 2020 and 2050. At current levels of health system performance (including access and referral), 6·1 million (44·9%) of these children will be undiagnosed. Between 2020 and 2050, 11·1 million children will die from cancer if no additional investments are made to improve access to health-care services or childhood cancer treatment. Of this total, 9·3 million children (84·1%) will be in low-income and lower-middle-income countries. This burden could be vastly reduced with new funding to scale up cost-effective interventions. Simultaneous comprehensive scale-up of interventions could avert 6·2 million deaths in children with cancer in this period, more than half (56·1%) of the total number of deaths otherwise projected. Taking excess mortality risk into consideration, this reduction in the number of deaths is projected to produce a gain of 318 million life-years. In addition, the global lifetime productivity gains of US$2580 billion in 2020–50 would be four times greater than the cumulative treatment costs of $594 billion, producing a net benefit of $1986 billion on the global investment: a net return of $3 for every $1 invested. In sum, the burden of childhood cancer, which has been grossly underestimated in the past, can be effectively diminished to realise massive health and economic benefits and to avert millions of needless deaths.
  •  
585.
  •  
586.
  •  
587.
  • Bernatsky, S, et al. (författare)
  • Non-Hodgkin's lymphoma in systemic lupus erythematosus
  • 2005
  • Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 1468-2060 .- 0003-4967. ; 64:10, s. 1507-1509
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Recent evidence supports an association between systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). Objectives: To describe demographic factors, subtypes, and survival of patients with SLE who develop NHL. Methods: A multi-site cohort of 9547 subjects with definite SLE was assembled. Subjects at each centre were linked to regional tumour registries to determine cancer cases occurring after SLE diagnosis. For the NHL cases ascertained, descriptive statistics were calculated, and NHL subtype frequency and median survival time of patients determined. Results: 42 cases of NHL occurred in the patients with SLE during the 76 948 patient-years of observation. The median age of patients at NHL diagnosis was 57 years. Thirty six (86%) of the 42 patients developing NHL were women, reflecting the female predominance of the cohort. In the patients, aggressive histological subtypes appeared to predominate, with the most commonly identified NHL subtype being diffuse large B cell ( 11 out of 21 cases for which histological subtype was available). Twenty two of the patients had died a median of 1.2 years after lymphoma diagnosis. Conclusions: These data suggest aggressive disease in patients with SLE who develop NHL. Continuing work should provide further insight into the patterns of presentation, prognosis, and aetiology of NHL in SLE.
  •  
588.
  •  
589.
  •  
590.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 581-590 av 591
Typ av publikation
tidskriftsartikel (451)
konferensbidrag (4)
rapport (1)
forskningsöversikt (1)
bokkapitel (1)
Typ av innehåll
refereegranskat (575)
övrigt vetenskapligt/konstnärligt (6)
Författare/redaktör
Chen, X. (478)
Brau, J. E. (472)
Clark, A. (472)
Ferrere, D. (472)
Escobar, C. (471)
Hill, J. C. (471)
visa fler...
Chouridou, S. (469)
Gallop, B. J. (469)
Jain, V. (469)
Jones, G. (469)
Lacasta, C. (469)
Baker, O. K. (468)
Dam, M. (468)
Dawson, I. (468)
Ferrari, P. (468)
Fox, H. (468)
Garcia, C. (468)
Hajduk, Z. (468)
Hance, M. (468)
Hughes, G. (468)
Issever, C. (468)
Kohriki, T. (468)
Lee, S. C. (468)
Aleksa, M. (467)
Barr, A. J. (467)
Beck, H. P. (467)
Calvet, D. (467)
Carli, T. (467)
Catinaccio, A. (467)
Chen, H. (467)
Cindro, V. (467)
Costa, M. J. (467)
Costanzo, D. (467)
D'Auria, S. (467)
Davidek, T. (467)
Dobos, D. (467)
Elsing, M. (467)
Farbin, A. (467)
Ferrer, A. (467)
Flick, T. (467)
Francis, D. (467)
Fuster, J. (467)
Gorini, B. (467)
Hawkings, R. J. (467)
Hervas, L. (467)
Jansen, E. (467)
Jones, T. J. (467)
Kersten, S. (467)
Laplace, S. (467)
Lester, C. G. (467)
visa färre...
Lärosäte
Lunds universitet (502)
Uppsala universitet (273)
Stockholms universitet (124)
Kungliga Tekniska Högskolan (90)
Karolinska Institutet (55)
Göteborgs universitet (14)
visa fler...
Chalmers tekniska högskola (6)
Umeå universitet (5)
Linköpings universitet (2)
Jönköping University (1)
Linnéuniversitetet (1)
Högskolan Dalarna (1)
visa färre...
Språk
Engelska (591)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (361)
Medicin och hälsovetenskap (57)
Teknik (1)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy